In 2022, the phase I/II study confirmed the promising results: 4 out of 8 recruited patients achieved MRD-negative MLFS, 1 patient had MLFS and MRD positivity, 1 patient had CRi and MRD positivity, 1 patient had PR, and 1 patient remained at stable disease (SD) status but had CLL1-positive AML blast clearance [79]. Here, CLEC12A is linked to acute myeloid leukemia.